Preventing Venous Thromboembolism in Patients with Cancer by D&apos et al.
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 380;22 nejm.org May 30, 20192180
plification after cessation of treatment with a 
drug that has a long half-life (5.5 months for 
bedaquiline).5
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Preventing Venous Thromboembolism in Patients with Cancer
To the Editor: Central venous catheters are 
commonly used for long periods in patients with 
cancer, and a nonnegligible increased risk of ve-
nous thromboembolism is associated with these 
devices.1 Nonetheless, the presence of a central 
venous catheter is not included as a component 
of established risk scores to determine which pa-
tients could benefit from thromboprophylaxis. 
We and others have reported on the role of anti-
coagulation (heparin or vitamin K antagonists) 
in reducing the risk of venous thromboembolism 
related to the use of a central venous catheter.1,2 
Carrier et al. (Feb. 21 issue)3 report the results 
of the Apixaban for the Prevention of Venous 
Thromboembolism in High-Risk Ambulatory Can-
cer Patients (AVERT) trial, and, in the same issue 
of the Journal, Khorana et al.4 report the results of 
the CASSINI trial. These two pivotal trials eval-
uated factor Xa inhibitors for the prevention of 
venous thromboembolism in patients with can-
cer. The accompanying editorial by Agnelli5 ele-
gantly merged the data from these trials, which 
showed a reduced risk of venous thromboembo-
lism among patients who received thrombopro-
phylaxis with factor Xa inhibitors.
Unfortunately, neither trial stratified pa-
tients or reported trial outcomes with adjust-
ment for central venous catheter–related venous 
thromboembolism. Therefore, we strongly en-
courage researchers from both trial groups to 
explore the effect of central venous catheters. 
Although this was not a prespecified analysis, 
it would increase our knowledge of the roles 
of central venous catheters and of factor Xa in-
hibitors as independent risk factors for venous 
thromboembolism. This information would 
help us to evaluate whether the use of central 
venous catheters should be considered in the 
decision-making process regarding thrombopro-
phylaxis.
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Dr. Carrier and colleagues reply: Stratifica-
tion of ambulatory patients with cancer according 
to their underlying risk of venous thromboembo-
lism is challenging. As highlighted by D’Ambrosio 
et al., known important risk factors may not be 
included in risk scores such as the Khorana score 
(range, 0 to 6, with higher scores indicating a 
higher risk of venous thromboembolism). For ex-
ample, although central venous catheters may 
be associated with an increased risk of venous 
thromboembolism, 223 of the 574 patients (38.9%) 
who underwent randomization in the AVERT 
trial had a central venous catheter in place, and 
a proximal deep-vein thrombosis of the upper 
limbs developed in only 7 of these 223 patients 
(3.1%) over a period of 6 months.
The role of direct oral anticoagulants in pre-
venting deep-vein thrombosis of the upper limbs 
is the subject of an ongoing pilot randomized 
trial assessing feasibility (ClinicalTrials.gov num-
ber, NCT03506815).1 Nonetheless, the Khorana 
score appears to be clinically relevant. Although 
approximately two thirds of the patients enrolled 
in our trial had a Khorana score of 2, the risk of a 
major venous thromboembolism was high in this 
subgroup: it occurred in 16 of 190 patients in the 
placebo group (8.4%) and in 6 of 186 patients in 
the apixaban group (3.2%) (risk difference, −5.2 
percentage points; 95% confidence interval, −10.3 
to −3.7).
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Dr. Khorana and colleagues reply: D’Ambro-
sio and colleagues raise an important question 
regarding the risk of thrombosis in an upper 
limb among patients with central venous cathe-
ters. Prophylactic anticoagulation is not well es-
tablished because of conflicting data and lower 
rates of thromboembolism reported in contem-
porary studies1 than in previous studies.2 A Kho-
rana score of 3 or higher has been shown to be a 
risk factor for such events.3 In the CASSINI trial, 
which involved patients with a Khorana score of 
2 or higher, 424 of 841 patients had a central ve-
nous catheter. Of these, 1 of 218 patients (0.5%) 
in the rivaroxaban group and 5 of 206 patients 
(2.4%) in the placebo group were adjudicated to 
have a deep-vein thrombosis in an upper limb 
while receiving the trial drug or placebo. In addi-
tion, excluding infectious complications, 2.8% of 
the patients in the rivaroxaban group and 4.9% 
in the placebo group had a catheter failure or 
other complications of a central venous catheter 
during the trial period. Our exploratory post hoc 
analysis suggests a reduced risk of thrombosis in 
an upper limb and noninfectious catheter failure 
with the use of daily rivaroxaban; these findings 
may be helpful in decision making regarding the 
use of thromboprophylaxis in outpatients with 
cancer.
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